Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register

I Y K Iskandar; D M Ashcroft; R B Warren; Z Z N Yiu; K McElhone; M Lunt; J N W N Barker; A D Burden; A D Ormerod; N J Reynolds; C H Smith; C E M Griffiths

doi:10.1111/bjd.13908

Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register

I Y K Iskandar, D M Ashcroft, R B Warren, Z Z N Yiu, K McElhone, M Lunt, J N W N Barker, A D Burden, A D Ormerod, N J Reynolds, C H Smith, C E M Griffiths

Research output: Contribution to journal › Article › peer-review

86 Citations (Scopus)

Abstract

BACKGROUND: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational cohort designed to assess the long-term safety of biologic and conventional systemic therapies used for adults with moderate-to-severe psoriasis in the U.K. and Republic of Ireland.

OBJECTIVES: To describe the demographics, disease severity and comorbidities of patients with psoriasis on enrolment into BADBIR, and to highlight differences in those commencing biologics compared with those on conventional systemic therapies.

METHODS: Baseline data were collected from 151 dermatology departments in the U.K. and Republic of Ireland. Descriptive analysis was conducted.

RESULTS: As of August 2014, 8399 patients were registered with BADBIR; 5065 (60%) received biologics, of whom 52·8% received adalimumab, 24·6% etanercept, 18·7% ustekinumab and 3·9% infliximab. In the comparator cohort 44·1% received methotrexate, 23·1% ciclosporin, 18·0% acitretin and 7·6% fumaric acid esters. Overall 4897 (58%) were male. Patients on biologics had a higher mean ± SD age and disease duration than patients on conventional systemic therapies (46·3 ± 12·7 vs. 44·3 ± 14·3 years and 23·0 ± 12·6 vs. 19·0 ± 13·4 years, respectively; both P < 0·001). Mean body mass index, Psoriasis Area and Severity Index and Dermatology Life Quality Index scores for patients on biologics were higher than for those on conventional systemic therapies (31·0 ± 7·2 vs. 30·1 ± 7·3 kg m(-2) ; 16·4 ± 8·3 vs. 15·5 ± 7·9 and 17·4 ± 7·5 vs. 15·0 ± 7·1, respectively; all P < 0·001). In total 71% of all patients had comorbidities and 47% had more than one comorbidity. The most frequent comorbidities were obesity (42·1%), hypertension (25·7%), depression (22·1%) and psoriatic arthritis (17·1%).

CONCLUSIONS: BADBIR is an invaluable resource to study the safety and effectiveness of both biologic and conventional systemic therapies. Understanding differences in baseline characteristics between cohorts is crucial in undertaking future pharmacovigilance studies.

Original language	English
Pages (from-to)	510-8
Number of pages	9
Journal	British Journal of Dermatology
Volume	173
Issue number	2
DOIs	https://doi.org/10.1111/bjd.13908
Publication status	Published - Aug 2015

Keywords

Adolescent
Adult
Age of Onset
Aged
Biological Factors
Comorbidity
Dermatologic Agents
Female
Humans
Male
Middle Aged
Prospective Studies
Psoriasis
Quality of Life
Registries
United Kingdom
Young Adult

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjd.13908

Cite this

Iskandar, I. Y. K., Ashcroft, D. M., Warren, R. B., Yiu, Z. Z. N., McElhone, K., Lunt, M., Barker, J. N. W. N., Burden, A. D., Ormerod, A. D., Reynolds, N. J., Smith, C. H., & Griffiths, C. E. M. (2015). Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. British Journal of Dermatology, 173(2), 510-8. https://doi.org/10.1111/bjd.13908

@article{f355ee0169424e4ca97b829df209ec24,

title = "Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register",

abstract = "BACKGROUND: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational cohort designed to assess the long-term safety of biologic and conventional systemic therapies used for adults with moderate-to-severe psoriasis in the U.K. and Republic of Ireland.OBJECTIVES: To describe the demographics, disease severity and comorbidities of patients with psoriasis on enrolment into BADBIR, and to highlight differences in those commencing biologics compared with those on conventional systemic therapies.METHODS: Baseline data were collected from 151 dermatology departments in the U.K. and Republic of Ireland. Descriptive analysis was conducted.RESULTS: As of August 2014, 8399 patients were registered with BADBIR; 5065 (60%) received biologics, of whom 52·8% received adalimumab, 24·6% etanercept, 18·7% ustekinumab and 3·9% infliximab. In the comparator cohort 44·1% received methotrexate, 23·1% ciclosporin, 18·0% acitretin and 7·6% fumaric acid esters. Overall 4897 (58%) were male. Patients on biologics had a higher mean ± SD age and disease duration than patients on conventional systemic therapies (46·3 ± 12·7 vs. 44·3 ± 14·3 years and 23·0 ± 12·6 vs. 19·0 ± 13·4 years, respectively; both P < 0·001). Mean body mass index, Psoriasis Area and Severity Index and Dermatology Life Quality Index scores for patients on biologics were higher than for those on conventional systemic therapies (31·0 ± 7·2 vs. 30·1 ± 7·3 kg m(-2) ; 16·4 ± 8·3 vs. 15·5 ± 7·9 and 17·4 ± 7·5 vs. 15·0 ± 7·1, respectively; all P < 0·001). In total 71% of all patients had comorbidities and 47% had more than one comorbidity. The most frequent comorbidities were obesity (42·1%), hypertension (25·7%), depression (22·1%) and psoriatic arthritis (17·1%).CONCLUSIONS: BADBIR is an invaluable resource to study the safety and effectiveness of both biologic and conventional systemic therapies. Understanding differences in baseline characteristics between cohorts is crucial in undertaking future pharmacovigilance studies.",

keywords = "Adolescent, Adult, Age of Onset, Aged, Biological Factors, Comorbidity, Dermatologic Agents, Female, Humans, Male, Middle Aged, Prospective Studies, Psoriasis, Quality of Life, Registries, United Kingdom, Young Adult",

author = "Iskandar, {I Y K} and Ashcroft, {D M} and Warren, {R B} and Yiu, {Z Z N} and K McElhone and M Lunt and Barker, {J N W N} and Burden, {A D} and Ormerod, {A D} and Reynolds, {N J} and Smith, {C H} and Griffiths, {C E M}",

note = "{\textcopyright} 2015 British Association of Dermatologists.",

year = "2015",

month = aug,

doi = "10.1111/bjd.13908",

language = "English",

volume = "173",

pages = "510--8",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "John Wiley & Sons, Ltd (10.1111)",

number = "2",

}

Iskandar, IYK, Ashcroft, DM, Warren, RB, Yiu, ZZN, McElhone, K, Lunt, M, Barker, JNWN, Burden, AD, Ormerod, AD, Reynolds, NJ , Smith, CH & Griffiths, CEM 2015, 'Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register', British Journal of Dermatology, vol. 173, no. 2, pp. 510-8. https://doi.org/10.1111/bjd.13908

TY - JOUR

T1 - Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register

AU - Iskandar, I Y K

AU - Ashcroft, D M

AU - Warren, R B

AU - Yiu, Z Z N

AU - McElhone, K

AU - Lunt, M

AU - Barker, J N W N

AU - Burden, A D

AU - Ormerod, A D

AU - Reynolds, N J

AU - Smith, C H

AU - Griffiths, C E M

PY - 2015/8

Y1 - 2015/8

N2 - BACKGROUND: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational cohort designed to assess the long-term safety of biologic and conventional systemic therapies used for adults with moderate-to-severe psoriasis in the U.K. and Republic of Ireland.OBJECTIVES: To describe the demographics, disease severity and comorbidities of patients with psoriasis on enrolment into BADBIR, and to highlight differences in those commencing biologics compared with those on conventional systemic therapies.METHODS: Baseline data were collected from 151 dermatology departments in the U.K. and Republic of Ireland. Descriptive analysis was conducted.RESULTS: As of August 2014, 8399 patients were registered with BADBIR; 5065 (60%) received biologics, of whom 52·8% received adalimumab, 24·6% etanercept, 18·7% ustekinumab and 3·9% infliximab. In the comparator cohort 44·1% received methotrexate, 23·1% ciclosporin, 18·0% acitretin and 7·6% fumaric acid esters. Overall 4897 (58%) were male. Patients on biologics had a higher mean ± SD age and disease duration than patients on conventional systemic therapies (46·3 ± 12·7 vs. 44·3 ± 14·3 years and 23·0 ± 12·6 vs. 19·0 ± 13·4 years, respectively; both P < 0·001). Mean body mass index, Psoriasis Area and Severity Index and Dermatology Life Quality Index scores for patients on biologics were higher than for those on conventional systemic therapies (31·0 ± 7·2 vs. 30·1 ± 7·3 kg m(-2) ; 16·4 ± 8·3 vs. 15·5 ± 7·9 and 17·4 ± 7·5 vs. 15·0 ± 7·1, respectively; all P < 0·001). In total 71% of all patients had comorbidities and 47% had more than one comorbidity. The most frequent comorbidities were obesity (42·1%), hypertension (25·7%), depression (22·1%) and psoriatic arthritis (17·1%).CONCLUSIONS: BADBIR is an invaluable resource to study the safety and effectiveness of both biologic and conventional systemic therapies. Understanding differences in baseline characteristics between cohorts is crucial in undertaking future pharmacovigilance studies.

AB - BACKGROUND: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational cohort designed to assess the long-term safety of biologic and conventional systemic therapies used for adults with moderate-to-severe psoriasis in the U.K. and Republic of Ireland.OBJECTIVES: To describe the demographics, disease severity and comorbidities of patients with psoriasis on enrolment into BADBIR, and to highlight differences in those commencing biologics compared with those on conventional systemic therapies.METHODS: Baseline data were collected from 151 dermatology departments in the U.K. and Republic of Ireland. Descriptive analysis was conducted.RESULTS: As of August 2014, 8399 patients were registered with BADBIR; 5065 (60%) received biologics, of whom 52·8% received adalimumab, 24·6% etanercept, 18·7% ustekinumab and 3·9% infliximab. In the comparator cohort 44·1% received methotrexate, 23·1% ciclosporin, 18·0% acitretin and 7·6% fumaric acid esters. Overall 4897 (58%) were male. Patients on biologics had a higher mean ± SD age and disease duration than patients on conventional systemic therapies (46·3 ± 12·7 vs. 44·3 ± 14·3 years and 23·0 ± 12·6 vs. 19·0 ± 13·4 years, respectively; both P < 0·001). Mean body mass index, Psoriasis Area and Severity Index and Dermatology Life Quality Index scores for patients on biologics were higher than for those on conventional systemic therapies (31·0 ± 7·2 vs. 30·1 ± 7·3 kg m(-2) ; 16·4 ± 8·3 vs. 15·5 ± 7·9 and 17·4 ± 7·5 vs. 15·0 ± 7·1, respectively; all P < 0·001). In total 71% of all patients had comorbidities and 47% had more than one comorbidity. The most frequent comorbidities were obesity (42·1%), hypertension (25·7%), depression (22·1%) and psoriatic arthritis (17·1%).CONCLUSIONS: BADBIR is an invaluable resource to study the safety and effectiveness of both biologic and conventional systemic therapies. Understanding differences in baseline characteristics between cohorts is crucial in undertaking future pharmacovigilance studies.

KW - Adolescent

KW - Adult

KW - Age of Onset

KW - Aged

KW - Biological Factors

KW - Comorbidity

KW - Dermatologic Agents

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Psoriasis

KW - Quality of Life

KW - Registries

KW - United Kingdom

KW - Young Adult

U2 - 10.1111/bjd.13908

DO - 10.1111/bjd.13908

M3 - Article

C2 - 25989336

SN - 0007-0963

VL - 173

SP - 510

EP - 518

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 2

ER -

Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this